Growth Metrics

Anika Therapeutics (ANIK) Retained Earnings (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Retained Earnings for 16 consecutive years, with -$5.0 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 26.89% to -$5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.0 million through Dec 2025, up 26.89% year-over-year, with the annual reading at -$5.0 million for FY2025, 26.89% up from the prior year.
  • Retained Earnings for Q4 2025 was -$5.0 million at Anika Therapeutics, roughly flat from -$4.9 million in the prior quarter.
  • The five-year high for Retained Earnings was $224.3 million in Q1 2021, with the low at -$7.5 million in Q3 2022.
  • Average Retained Earnings over 5 years is $68.3 million, with a median of -$4.9 million recorded in 2021.
  • The sharpest move saw Retained Earnings soared 3821.29% in 2021, then crashed 105.3% in 2024.
  • Over 5 years, Retained Earnings stood at -$5.7 million in 2021, then skyrocketed by 3785.19% to $210.7 million in 2022, then crashed by 39.23% to $128.1 million in 2023, then tumbled by 105.3% to -$6.8 million in 2024, then rose by 26.89% to -$5.0 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$5.0 million, -$4.9 million, and $62.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.